Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice

Archives of Pharmacal Research

Volumn 29, Issue 9, 2006, Pages 768-776

  Park, Sang Hyun ^a   Lee, Sang Gil ^a   Kang, Sung Keel ^a   Chung, Sung Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Acanthopanax senticosus stem bark; Glucose 6 phosphatase; Insulin resistance; Lipogenic enzymes; Non alcoholic fatty liver disease

Indexed keywords

EID: 33749364335     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02974078     Document Type: Article

References (20)

1. Angulo, P., Nonalcoholic fatty liver disease. New Engl. J. Med., 346, 1221-1231 (2002).
2. Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
3. Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., and Friedman, J. M., Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science, 297, 240-243 (2002).
4. Cohen, P., Zhao, C., Cai, X., Montez, J. M., Rohani, S. C., Feinstein, P., Mombaerts, P., and Friedman, J. M., Selective deletion of leptin receptor in neurons leads to obesity. J. Clin. Invest., 108, 1113-1121 (2001).
5. Cusi, K., Consol, A., and DeFronzo, R. A., Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocr. and Metab., 81, 4059-4067 (1996).
6. Davies, G. F., Khandelwal, R. L., Wu, L., Juurlink, B. H., and Roesler, W. J., Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem Pharmacol., 62, 1071-1079 (2001).
7. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with NAFLD. J. Clin. Invest., 115, 1343-1351 (2005).
8. Hookman, P. and Barkin, J. S., Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. Am. J. Gastroenterol., 98, 2093-2097 (2002).
9. Liang, C. P. and Tall, A. R., Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem., 276, 49066-49076 (2001).
10. Lin, H. Z., Yang, S. Q., Kujhada, F., Ronnet, G., and Diehl, A. M., Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice. Nat. Med., 6, 998-1003 (2000).
11. Manco, M., Calvani, M., and Mingrone, G., Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes. Obes. Metab., 6, 402-413 (2004).
12. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M., and Melchionda, N., Metformin in non-alcoholic steatohepatitis. Lancet., 358, 893-894 (2001).
13. Matthews, D. R., Hosker, J. P., Rudenky, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 28, 412-419 (1985).
14. Mithieux, G., New knowledge regarding glucose-6-phosphatase gene and protein and their roles in the regulation of glucose metabolism. Eur. J. Endocr., 136, 137-145 (1997).
15. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., and Bacon, B. R., Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 38, 1008-1017 (2003).
16. Nishioka, S., Kinoshita, H., Takeda, H., and Okano, G., Phenolic compounds from the stem bark of Acanthopanax senticosus and their pharmacological effect in chronic swimming stressed rats. Chem. Pharm. Bull., 38, 1763-1765 (1990).
17. Schwarz, J. M., Linfoot, P., Date, D., and Aghajanian, K., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high fat, low carbohydrate and low fat, high catbohydrate isoenergetic diets. Am. J. Clin. Nutr., 77, 43-50 (2003).
18. Shimomura, I., Bashmakov, Y., and Horton, J. D., Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem., 274, 30028-30032 (1999).
19. Trinder, P., Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen. J. Clin. Pathol., 22, 158-161 (1969).
20. Tolman, K. G., Fonseca, V., Tan, M. H., and Dalpiaz, A., Narative review: hepatobiliary disease in type 2 diabetes mellitus. Annu. Intern. Med., 141, 946-956 (2004).